Vimarsana
Biggest News Aggregation in the World

Page 17 - Advanced Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Solid Tumors Today - Breaking & Trending Today

Imugene Limited secures FDA approval for two clinical trials of promising oncology drug candidates - Vimarsana News

Imugene Limited secures FDA approval for two clinical trials of promising oncology drug candidates

“To achieve two INDs for our programs (OV and B Cell) concurrently is an outstanding result for the team," says MD.

Sarah Cannon Research Institute: Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO Annual Meeting - Vimarsana News

Sarah Cannon Research Institute: Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO Annual Meeting

119 Abstracts and Presentations Featuring Sarah Cannon's Clinical Research and Care Insights Today, Sarah Cannon announced it will present its latest cancer research insights at the American Society

Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021 - Vimarsana News

Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021

Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021 Gilead Sciences, Inc. and Kite, a Gilead Company, today announced that 16 abstracts representing the breadth of the Gilead-Kite Oncology portfolio will be presented at the American Society of Clinical Oncology Annual Meeting from June 4-8, 2021. The abstracts, including two oral presentations, expand on the clinical profiles of Gilead’s antibody-drug conjugate as well as Kite’s chimeric antigen receptor T-cell … Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that...

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021 - Vimarsana News

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021 LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer New Data From the Phase 2 FIGHT Trial with Bemarituzumab in Advanced Gastric and Gastroesophageal Junction Cancers News provided by Share this article Share this article THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new data from its expanding oncology pipeline and marketed portfolio will be presented during the 20...

Salarius Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentations at the 2021 American Society of Clinical Oncology Annual Meeting - Vimarsana News

Salarius Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentations at the 2021 American Society of Clinical Oncology Annual Meeting

Message : Required fields HOUSTON, April 19, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that all three submitted abstracts detailing research involving seclidemstat were accepted for poster presentations, with one abstract also selected for a poster discussion session, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. ASCO will be held virtually from June 4-8, 2021. “We are ve...